当前蛋白身份:P36897 重新检索
本组结构的主要差异维度
构建体不同 突变/修饰不同 组装状态不同 配体/离子不同 实验方法不同 实验环境不同 结构质量指标不同

差异标签只比较当前检索结果;所有PDB和assembly原始记录仍分别保留。

相关结构差异明细

一行代表一个 PDB 条目中的一个 biological assembly;同一蛋白的多个单体会分别列出。

PDB 条目 Assembly / 聚集状态 构建体 突变与修饰 配体、离子与非聚合物 实验方法 实验环境 结构质量
1B6C CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12 提交 1999-01-13 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 162–503(342 aa) 片段:CYTOPLASMIC PORTION
未记录 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 8.5;pH 8.5
分辨率 2.60 Å R-free 0.269
1B6C CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12 提交 1999-01-13 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 162–503(342 aa) 片段:CYTOPLASMIC PORTION
未记录 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 8.5;pH 8.5
分辨率 2.60 Å R-free 0.269
1B6C CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12 提交 1999-01-13 Assembly 3 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 F 162–503(342 aa) 片段:CYTOPLASMIC PORTION
未记录 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 8.5;pH 8.5
分辨率 2.60 Å R-free 0.269
1B6C CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12 提交 1999-01-13 Assembly 4 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 H 162–503(342 aa) 片段:CYTOPLASMIC PORTION
未记录 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 8.5;pH 8.5
分辨率 2.60 Å R-free 0.269
1B6C CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12 提交 1999-01-13 Assembly 5 蛋白异源复合物 异源复合物;蛋白 × 8 PDB 声明:octameric(8) 与蛋白数一致
链 B 162–503(342 aa) 片段:CYTOPLASMIC PORTION
链 D 162–503(342 aa) 片段:CYTOPLASMIC PORTION
链 F 162–503(342 aa) 片段:CYTOPLASMIC PORTION
链 H 162–503(342 aa) 片段:CYTOPLASMIC PORTION
未记录 SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray结晶条件 pH 8.5;pH 8.5
分辨率 2.60 Å R-free 0.269
1IAS CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12 提交 2001-03-23 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 A 162–503(342 aa) 片段:CYTOPLASMIC DOMAIN (RESIDUES 162-503)
链 B 162–503(342 aa) 片段:CYTOPLASMIC DOMAIN (RESIDUES 162-503)
链 C 162–503(342 aa) 片段:CYTOPLASMIC DOMAIN (RESIDUES 162-503)
链 D 162–503(342 aa) 片段:CYTOPLASMIC DOMAIN (RESIDUES 162-503)
链 E 162–503(342 aa) 片段:CYTOPLASMIC DOMAIN (RESIDUES 162-503)
未记录 SO4 SULFATE ION × 15 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.8;277 K;100 mM MES pH 5.8, 2.4 M ammonium sulfate, 10 % glycerol v/v, 150 mM NaCl, 1 mM NPC-30345, VAPOR DIFFUSION, HANGING DROP, temperature 277K
分辨率 2.90 Å R-free 0.284
1PY5 Crystal Structure of TGF-beta receptor I kinase with inhibitor 提交 2003-07-08 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 175–500(326 aa) 片段:Truncated kinase domain, residues 175-500
未记录 SO4 SULFATE ION × 1 PY1 4-(3-PYRIDIN-2-YL-1H-PYRAZOL-4-YL)QUINOLINE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.6;298 K;Tris, ATP, MgCl2, DTT, Hexanediol, PEG4000, LiSO4, pH 7.6, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
分辨率 2.30 Å R-free 0.292
1RW8 Crystal Structure of TGF-beta receptor I kinase with ATP site inhibitor 提交 2003-12-16 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–500(301 aa) 片段:Truncated kinase domain (residues 200-500)
未记录 580 3-(4-FLUOROPHENYL)-2-(6-METHYLPYRIDIN-2-YL)-5,6-DIHYDRO-4H-PYRROLO[1,2-B]PYRAZOLE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;Tris, ATP, MgCl2, DTT, Hexanediol, PEG 4000, LiSo4, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 2.40 Å R-free 0.291
1VJY Crystal Structure of a Naphthyridine Inhibitor of Human TGF-beta Type I Receptor 提交 2004-04-07 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–303(303 aa) 片段:protein kinase
未记录 460 2-[5-(6-METHYLPYRIDIN-2-YL)-2,3-DIHYDRO-1H-PYRAZOL-4-YL]-1,5-NAPHTHYRIDINE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 8;278 K;20% PEG 4000, 0.1M Tris HCl, 0.2 M magnesium chloride, pH 8.0, vapor diffusion/sitting drop, temperature 278K, VAPOR DIFFUSION, SITTING DROP
分辨率 2.00 Å R-free 0.275
2L5S Solution structure of the extracellular domain of the TGF-beta type I receptor 提交 2010-11-04 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 31–115(85 aa)
非标准单体:是(mmCIF未提供具体位点) 未记录非水小分子 SOLUTION NMR
NMR测量条件 pH 7.2;300 K;离子强度(mmCIF原始值)0.025;压力 ambient
NMR样品组成 1 mM [U-100% 13C; U-100% 15N] TbRI-1, 95% H2O/5% D2O | 95% H2O/5% D2O
分辨率未提供
2PJY Structural basis for cooperative assembly of the TGF-beta signaling complex 提交 2007-04-16 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 C 33–111(79 aa) 片段:extracellular domain
突变:M70S 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;10-20% PEG 3350, 0.4-0.65 M calcium acetate, 0.1-0.25M NaCl, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 3.00 Å R-free 0.297
2WOT ALK5 IN COMPLEX WITH 4-((5,6-dimethyl-2-(2-pyridyl)-3-pyridyl)oxy)-N-(3,4,5-trimethoxyphenyl)pyridin-2-amine 提交 2009-07-28 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa) 片段:CATALYTIC DOMAIN, RESIDUES 200-503
未记录 ZZG 4-[(5,6-DIMETHYL-2,2'-BIPYRIDIN-3-YL)OXY]-N-(3,4,5-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;SITTING DROP METHOD. DROPS PROTEIN-PRECIPITANT 1-1, PROTEIN: 10MG/ML ALK5, PRECIPITANT: 20-30% PEG8K, 100 MM PCTP BUFFER PH 8.5-9.2, 0.2 M NAAC
分辨率 1.85 Å R-free 0.221
2WOU ALK5 IN COMPLEX WITH 4-((4-((2,6-dimethyl-3-pyridyl)oxy)-2-pyridyl) amino)benzenesulfonamide 提交 2009-07-28 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa) 片段:CATALYTIC DOMAIN, RESIDUES 200-503
未记录 EDO 1,2-ETHANEDIOL × 1 ZZF 4-({4-[(2,6-DIMETHYLPYRIDIN-3-YL)OXY]PYRIDIN-2-YL}AMINO)BENZENESULFONAMIDE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;SITTING DROP METHOD. DROPS PROTEIN-PRECIPITANT 1-1, PROTEIN: 10MG/ML ALK5, PRECIPITANT: 20-30% PEG8K, 100 MM PCTP BUFFER PH 8.5-9.2, 0.2 M NAAC
分辨率 2.30 Å R-free 0.302
2X7O Crystal structure of TGFbRI complexed with an indolinone inhibitor 提交 2010-03-03 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 162–503(342 aa) 片段:CYTOPLASMIC DOMAIN, RESIDUES 162-503
未记录 ZOP (3Z)-N-ETHYL-N-METHYL-2-OXO-3-(PHENYL{[4-(PIPERIDIN-1-YLMETHYL)PHENYL]AMINO}METHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-6-CARBOXAMIDE × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7.2;1.5 M AMMONIUM SULFATE, 0.1 M GLYCINE PH 7.25
分辨率 3.70 Å R-free 0.273
2X7O Crystal structure of TGFbRI complexed with an indolinone inhibitor 提交 2010-03-03 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 162–503(342 aa) 片段:CYTOPLASMIC DOMAIN, RESIDUES 162-503
未记录 ZOP (3Z)-N-ETHYL-N-METHYL-2-OXO-3-(PHENYL{[4-(PIPERIDIN-1-YLMETHYL)PHENYL]AMINO}METHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-6-CARBOXAMIDE × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7.2;1.5 M AMMONIUM SULFATE, 0.1 M GLYCINE PH 7.25
分辨率 3.70 Å R-free 0.273
2X7O Crystal structure of TGFbRI complexed with an indolinone inhibitor 提交 2010-03-03 Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 C 162–503(342 aa) 片段:CYTOPLASMIC DOMAIN, RESIDUES 162-503
未记录 ZOP (3Z)-N-ETHYL-N-METHYL-2-OXO-3-(PHENYL{[4-(PIPERIDIN-1-YLMETHYL)PHENYL]AMINO}METHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-6-CARBOXAMIDE × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7.2;1.5 M AMMONIUM SULFATE, 0.1 M GLYCINE PH 7.25
分辨率 3.70 Å R-free 0.273
2X7O Crystal structure of TGFbRI complexed with an indolinone inhibitor 提交 2010-03-03 Assembly 4 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 D 162–503(342 aa) 片段:CYTOPLASMIC DOMAIN, RESIDUES 162-503
未记录 ZOP (3Z)-N-ETHYL-N-METHYL-2-OXO-3-(PHENYL{[4-(PIPERIDIN-1-YLMETHYL)PHENYL]AMINO}METHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-6-CARBOXAMIDE × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7.2;1.5 M AMMONIUM SULFATE, 0.1 M GLYCINE PH 7.25
分辨率 3.70 Å R-free 0.273
2X7O Crystal structure of TGFbRI complexed with an indolinone inhibitor 提交 2010-03-03 Assembly 5 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 E 162–503(342 aa) 片段:CYTOPLASMIC DOMAIN, RESIDUES 162-503
未记录 ZOP (3Z)-N-ETHYL-N-METHYL-2-OXO-3-(PHENYL{[4-(PIPERIDIN-1-YLMETHYL)PHENYL]AMINO}METHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-6-CARBOXAMIDE × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7.2;1.5 M AMMONIUM SULFATE, 0.1 M GLYCINE PH 7.25
分辨率 3.70 Å R-free 0.273
3FAA Crystal structure of TGFbRI complexed with a 2-aminoimidazole inhibitor 提交 2008-11-16 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 162–503(342 aa) 片段:GS and Kinase domains: UNP residues 162-503
未记录 55F N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide × 1 PO4 PHOSPHATE ION × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.4;293 K;Na/K phosphate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 3.35 Å R-free 0.271
3FAA Crystal structure of TGFbRI complexed with a 2-aminoimidazole inhibitor 提交 2008-11-16 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 162–503(342 aa) 片段:GS and Kinase domains: UNP residues 162-503
未记录 55F N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide × 1 PO4 PHOSPHATE ION × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.4;293 K;Na/K phosphate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 3.35 Å R-free 0.271
3FAA Crystal structure of TGFbRI complexed with a 2-aminoimidazole inhibitor 提交 2008-11-16 Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 C 162–503(342 aa) 片段:GS and Kinase domains: UNP residues 162-503
未记录 55F N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.4;293 K;Na/K phosphate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 3.35 Å R-free 0.271
3FAA Crystal structure of TGFbRI complexed with a 2-aminoimidazole inhibitor 提交 2008-11-16 Assembly 4 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 D 162–503(342 aa) 片段:GS and Kinase domains: UNP residues 162-503
未记录 55F N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide × 1 PO4 PHOSPHATE ION × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.4;293 K;Na/K phosphate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 3.35 Å R-free 0.271
3FAA Crystal structure of TGFbRI complexed with a 2-aminoimidazole inhibitor 提交 2008-11-16 Assembly 5 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 E 162–503(342 aa) 片段:GS and Kinase domains: UNP residues 162-503
未记录 55F N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide × 1 PO4 PHOSPHATE ION × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.4;293 K;Na/K phosphate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 3.35 Å R-free 0.271
3GXL ALK-5 kinase complex with GW857175 提交 2009-04-02 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 201–503(303 aa) 片段:kinase domain, residues 201-503
未记录 QIG N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;vapor diffusion
分辨率 1.80 Å R-free 0.263
3HMM Structure of Alk5 + GW855857 提交 2009-05-29 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 201–503(303 aa) 片段:KINASE DOMAIN, RESIDUES 201-503
未记录 855 2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;VAPOR DIFFUSION
分辨率 1.70 Å R-free 0.241
3KCF Crystal structure of TGFbRI complexed with a pyrazolone inhibitor 提交 2009-10-21 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 162–503(342 aa) 片段:UNP residues 162-503, GS AND KINASE DOMAINS
未记录 JZO 4-[3-(methoxymethyl)phenyl]-1,2-dimethyl-5-quinoxalin-6-yl-1,2-dihydro-3H-pyrazol-3-one × 1 PO4 PHOSPHATE ION × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.4;293 K;Sodium potassium phosphate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 2.80 Å R-free 0.278
3KCF Crystal structure of TGFbRI complexed with a pyrazolone inhibitor 提交 2009-10-21 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 162–503(342 aa) 片段:UNP residues 162-503, GS AND KINASE DOMAINS
未记录 JZO 4-[3-(methoxymethyl)phenyl]-1,2-dimethyl-5-quinoxalin-6-yl-1,2-dihydro-3H-pyrazol-3-one × 1 PO4 PHOSPHATE ION × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.4;293 K;Sodium potassium phosphate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 2.80 Å R-free 0.278
3KCF Crystal structure of TGFbRI complexed with a pyrazolone inhibitor 提交 2009-10-21 Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 C 162–503(342 aa) 片段:UNP residues 162-503, GS AND KINASE DOMAINS
未记录 JZO 4-[3-(methoxymethyl)phenyl]-1,2-dimethyl-5-quinoxalin-6-yl-1,2-dihydro-3H-pyrazol-3-one × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.4;293 K;Sodium potassium phosphate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 2.80 Å R-free 0.278
3KCF Crystal structure of TGFbRI complexed with a pyrazolone inhibitor 提交 2009-10-21 Assembly 4 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 D 162–503(342 aa) 片段:UNP residues 162-503, GS AND KINASE DOMAINS
未记录 JZO 4-[3-(methoxymethyl)phenyl]-1,2-dimethyl-5-quinoxalin-6-yl-1,2-dihydro-3H-pyrazol-3-one × 1 PO4 PHOSPHATE ION × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.4;293 K;Sodium potassium phosphate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 2.80 Å R-free 0.278
3KCF Crystal structure of TGFbRI complexed with a pyrazolone inhibitor 提交 2009-10-21 Assembly 5 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 E 162–503(342 aa) 片段:UNP residues 162-503, GS AND KINASE DOMAINS
未记录 JZO 4-[3-(methoxymethyl)phenyl]-1,2-dimethyl-5-quinoxalin-6-yl-1,2-dihydro-3H-pyrazol-3-one × 1 PO4 PHOSPHATE ION × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.4;293 K;Sodium potassium phosphate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 2.80 Å R-free 0.278
3KFD Ternary complex of TGF-b1 reveals isoform-specific ligand recognition and receptor recruitment in the superfamily 提交 2009-10-27 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 I 31–115(85 aa) 片段:extracellular domain
链 J 31–115(85 aa) 片段:extracellular domain
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;pH 7;298 K;8-15% Peg 4000-8000, pH 7.0, VAPOR DIFFUSION, temperature 298K
分辨率 3.00 Å R-free 0.268
3KFD Ternary complex of TGF-b1 reveals isoform-specific ligand recognition and receptor recruitment in the superfamily 提交 2009-10-27 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 K 31–115(85 aa) 片段:extracellular domain
链 L 31–115(85 aa) 片段:extracellular domain
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;pH 7;298 K;8-15% Peg 4000-8000, pH 7.0, VAPOR DIFFUSION, temperature 298K
分辨率 3.00 Å R-free 0.268
3KFD Ternary complex of TGF-b1 reveals isoform-specific ligand recognition and receptor recruitment in the superfamily 提交 2009-10-27 Assembly 3 蛋白异源复合物 异源复合物;蛋白 × 12 PDB 声明:dodecameric(12) 与蛋白数一致
链 I 31–115(85 aa) 片段:extracellular domain
链 J 31–115(85 aa) 片段:extracellular domain
链 K 31–115(85 aa) 片段:extracellular domain
链 L 31–115(85 aa) 片段:extracellular domain
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;pH 7;298 K;8-15% Peg 4000-8000, pH 7.0, VAPOR DIFFUSION, temperature 298K
分辨率 3.00 Å R-free 0.268
3TZM TGF-beta Receptor type 1 in complex with SB431542 提交 2011-09-27 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa) 片段:kinase domain, UNP residues 200-503
未记录 085 4-[5-(1,3-benzodioxol-5-yl)-4-(pyridin-2-yl)-1H-imidazol-2-yl]benzamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8;293 K;100 mM Imidazole 10% PEG 8000, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 1.70 Å R-free 0.205
4X0M Selection of fragments for kinase inhibitor design: decoration is key 提交 2014-11-21 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa) 片段:UNP residues 200-503
未记录 3WA 4-aminopyrido[2,3-d]pyrimidin-5(8H)-one × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;293 K;0.1 M Tris-HCl, 240 mM Li2SO4, 24% PEG 4000, pH 7.5
分辨率 1.68 Å R-free 0.239
4X2F Selection of fragments for kinase inhibitor design: decoration is key 提交 2014-11-26 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa) 片段:UNP residues 200-503
未记录 3WJ 4-amino-8-(4-aminophenyl)pyrido[2,3-d]pyrimidin-5(8H)-one × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M Tris-HCl, 240 mM Li2SO4, 24% PEG 4000, pH 7.5
分辨率 1.49 Å R-free 0.191
4X2G Selection of fragments for kinase inhibitor design: decoration is key 提交 2014-11-26 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa) 片段:UNP residues 200-503
未记录 3WK 4-[(4-aminophenyl)amino]pyrido[2,3-d]pyrimidin-5(6H)-one × 1 SO4 SULFATE ION × 1 TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M Tris-HCl, 240 mM Li2SO4, 24% PEG 4000, pH 7.5
分辨率 1.51 Å R-free 0.185
4X2J Selection of fragments for kinase inhibitor design: decoration is key 提交 2014-11-26 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa)
未记录 3WN 4-[(3-aminophenyl)amino]pyrido[2,3-d]pyrimidin-5(8H)-one × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M Tris-HCl, 240 mM Li2SO4, 24% PEG 4000, pH 7.5
分辨率 1.69 Å R-free 0.184
4X2K Selection of fragments for kinase inhibitor design: decoration is key 提交 2014-11-26 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:MONOMERIC(1) 与蛋白数一致
链 A 200–503(304 aa)
未记录 3WO 4-[(3-aminophenyl)amino]pyrido[2,3-d]pyrimidin-5(6H)-one × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M Tris-HCl, 240 mM Li2SO4, 24% PEG 4000, pH 7.5
分辨率 1.69 Å R-free 0.184
4X2N Selection of fragments for kinase inhibitor design: decoration is key 提交 2014-11-26 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa) 片段:UNP residues 200-503
未记录 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M Tris-HCl, 240 mM Li2SO4, 24% PEG 4000, pH 7.5
分辨率 1.80 Å R-free 0.201
5E8S TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT) 提交 2015-10-14 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa) 片段:KINASE DOMAIN, UNP RESIDUES 200-503
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.6;277 K;23%(w/v) PEG3350, 3%(v/v) glcyerol
分辨率 1.45 Å R-free 0.188
5E8T TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) 提交 2015-10-14 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa) 片段:KINASE DOMAIN, UNP RESIDUES 200-503
突变:T204D GOL GLYCEROL × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.6;277 K;23%(w/v) PEG3350, 3%(v/v) glcyerol
分辨率 1.70 Å R-free 0.190
5E8U TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D,I211V,Y249F,S280T, Y282F,S287N,A350C,L352F) 提交 2015-10-14 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa) 片段:KINASE DOMAIN, UNP RESIDUES 200-503
突变:T204D,I211V,Y249F,S280T,Y282F,S287N,A350C,L352F GOL GLYCEROL × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.6;277 K;23%(w/v) PEG3350, 3%(v/v) glcyerol
分辨率 2.03 Å R-free 0.223
5E8W TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE 提交 2015-10-14 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa) 片段:KINASE DOMAIN, UNP RESIDUES 200-503
突变:T204D STU STAUROSPORINE × 1 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.6;277 K;23%(w/v) PEG3350, 3%(v/v) glcyerol
分辨率 1.86 Å R-free 0.186
5E8X TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D,I211V,Y249F,S280T, Y282F,S287N,A350C,L352F) IN COMPLEX WITH STAUROSPORINE 提交 2015-10-14 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa) 片段:KINASE DOMAIN, UNP RESIDUES 200-503
突变:T204D,I211V,Y249F,S280T, Y282F,S287N,A350C,L352F STU STAUROSPORINE × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.6;277 K;23%(w/v) PEG3350, 3%(v/v) glcyerol
分辨率 1.45 Å R-free 0.210
5E8Z TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3-AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2-CARBOXAMIDE 提交 2015-10-14 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa) 片段:KINASE DOMAIN, UNP RESIDUES 200-503
突变:T204D 5L4 3-amino-6-[4-(2-hydroxyethyl)phenyl]-N-[4-(morpholin-4-yl)pyridin-3-yl]pyrazine-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.6;277 K;23%(w/v) PEG3350, 3%(v/v) glcyerol
分辨率 1.51 Å R-free 0.207
5E90 TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D,I211V,Y249F, S280T,Y282F,S287N,A350C,L352F) IN COMPLEX WITH 3-AMINO-6- [4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2-CARBOXAMIDE 提交 2015-10-14 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa) 片段:KINASE DOMAIN, UNP RESIDUES 200-503
突变:T204D,I211V,Y249F,S280T,Y282F,S287N,A350C,L352F 5L4 3-amino-6-[4-(2-hydroxyethyl)phenyl]-N-[4-(morpholin-4-yl)pyridin-3-yl]pyrazine-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.6;277 K;23%(w/v) PEG3350, 3%(v/v) glcyerol
分辨率 2.05 Å R-free 0.218
5FRI ALK5 in complex witha an N-(4-anilino-2-pyridyl)acetamide inhibitor. 提交 2015-12-17 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–498(299 aa) 片段:UNP RESIDUES 200-498
未记录 EDO 1,2-ETHANEDIOL × 2 ZUQ N-[4-[(6-chloro-[1,3]dioxolo[4,5-b]pyridin-7-yl)amino]-2-pyridyl]cyclopropanecarboxamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;SITTING DROP METHOD. DROPS PROTEIN-PRECIPITANT 1-1, PROTEIN: 10MG/ML ALK5, PRECIPITANT: 20-30% PEG8K, 100 MM PCTP BUFFER PH 8.5-9.2, 0.2 M NAAC
分辨率 2.00 Å R-free 0.193
5QIK TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-{4-[3-(6-fluoropyridin-3-yl)-4-oxo-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridin-2-yl]pyridin-2-yl}acetamide 提交 2018-08-05 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa) 片段:KINASE DOMAIN, UNP RESIDUES 200-503
突变:T204D J2M N-{4-[3-(6-fluoropyridin-3-yl)-4-oxo-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridin-2-yl]pyridin-2-yl}acetamide × 1 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.6;277 K;23%(w/v) PEG3350, 3%(v/v) glcyerol
分辨率 1.58 Å R-free 0.190
5QIL TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-{4-[3-(6-METHOXYPYRIDIN-3-YL)-1H-PYRROLO[3,2-B]PYRIDIN-2-YL]PYRIDIN-2-YL}ACETAMIDE 提交 2018-08-05 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa) 片段:KINASE DOMAIN, UNP RESIDUES 200-503
突变:T204D J2V N-{4-[3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.6;277 K;23%(w/v) PEG3350, 3%(v/v) glcyerol
分辨率 1.98 Å R-free 0.210
5QIM TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-{4-[3-(5-METHOXYPYRIDIN-2-YL)-1H-PYRROLO[3,2-B] PYRIDIN-2-YL]PYRIDIN-2-YL}ACETAMIDE 提交 2018-08-05 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa) 片段:KINASE DOMAIN, UNP RESIDUES 200-503
未记录 J2Y N-{4-[3-(5-methoxypyridin-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.6;277 K;23%(w/v) PEG3350, 3%(v/v) glcyerol
分辨率 1.75 Å R-free 0.188
5QTZ TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 6-[1-(2,2-DIFLUOROETHYL)-4-(6-METHYLPYRIDIN-2-YL)-1H-IMIDAZOL-5-YL]IMIDAZO[1,2-A]PYRIDINE 提交 2019-11-19 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa) 片段:KINASE DOMAIN, UNP RESIDUES 200-503
突变:T204D QMY 6-[1-(2,2-difluoroethyl)-4-(6-methylpyridin-2-yl)-1H-imidazol-5-yl]imidazo[1,2-a]pyridine × 1 GOL GLYCEROL × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.6;277 K;23%(w/v) PEG3350, 3%(v/v) glcyerol
分辨率 1.83 Å R-free 0.200
5QU0 TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 6-[4-(3-CHLORO-4-FLUOROPHENYL)-1-(2-HYDROXYETHYL)-1H-IMIDAZOL-5-YL]IMIDAZO[1,2-B]PYRIDAZINE-3-CARBONITRILE 提交 2019-11-19 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa) 片段:KINASE DOMAIN, UNP RESIDUES 200-503
突变:YES QMV 6-[4-(3-chloro-4-fluorophenyl)-1-(2-hydroxyethyl)-1H-imidazol-5-yl]imidazo[1,2-b]pyridazine-3-carbonitrile × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.6;277 K;23%(w/v) PEG3350, 3%(v/v) glcyerol
分辨率 1.67 Å R-free 0.206
5USQ ALK-5 kinase inhibitor complex 提交 2017-02-13 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 123–421(299 aa) 片段:UNP residues 123-421
未记录 8LY N-[2-(5-chloro-2-fluorophenyl)pyridin-4-yl]-2-[(piperidin-4-yl)methyl]-2H-pyrazolo[4,3-b]pyridin-7-amine × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 9.2;293 K;16 % PEG 8000 100mM CHES pH 9.2
分辨率 2.55 Å R-free 0.231
6B8Y TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-(3-fluoropyridin-4-yl)-2-[6-(trifluoromethyl)pyridin-2-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine 提交 2017-10-09 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa) 片段:kinase domain
突变:T204D D0A N-(3-fluoropyridin-4-yl)-2-[6-(trifluoromethyl)pyridin-2-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.6;277 K;23%(w/v) PEG3350, 3%(v/v) glcyerol
分辨率 1.65 Å R-free 0.208
6MAC Ternary structure of GDF11 bound to ActRIIB-ECD and Alk5-ECD 提交 2018-08-27 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 6 PDB 声明:hexameric(6) 与蛋白数一致
链 K 33–112(80 aa)
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;293.15 K;.05-.15M sodium acetate 12-24% polyethylene glycol 8000 .05-.15M sodium thiocyanate
分辨率 2.34 Å R-free 0.267
8YHF The Crystal Structure of the Type I TGF beta receptor from Biortus. 提交 2024-02-28 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 162–503(342 aa)
未记录 A1D6I Vactosertib × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;0.02M K/Na PO4, 0.1M Bis-Tris propane pH6.5, 20% PEG3350
分辨率 1.40 Å R-free 0.192
8YHL The Crystal Structure of Tgf-Beta Type I Receptor (Alk5) from Biortus 提交 2024-02-28 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa)
未记录 A1D6I Vactosertib × 1 EDO 1,2-ETHANEDIOL × 2 ACY ACETIC ACID × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;0.1M MgAC2, 0.1M MES pH6.5, 10% PEG10,000
分辨率 1.47 Å R-free 0.193
9B9F Zebrafish Betaglycan Orphan Domain (zfBGo) in complex with TGF-B3 and extracellular domains of TGFBRI and TGFBRII 提交 2024-04-02 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 C 31–115(85 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;298 K;0.2 M lithium sulfate, 0.1 M tris pH 8.5, 30 %(w/v) polyethylene glycol 4000
分辨率 3.00 Å R-free 0.278
9B9F Zebrafish Betaglycan Orphan Domain (zfBGo) in complex with TGF-B3 and extracellular domains of TGFBRI and TGFBRII 提交 2024-04-02 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 H 31–115(85 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;298 K;0.2 M lithium sulfate, 0.1 M tris pH 8.5, 30 %(w/v) polyethylene glycol 4000
分辨率 3.00 Å R-free 0.278
9F6X Human transforming growth factor b type I receptor in complex with kinase inhibitor SB505124 提交 2024-05-02 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–500(301 aa)
未记录 A1IAZ 2-[5-(1,3-benzodioxol-5-yl)-2-~{tert}-butyl-1~{H}-imidazol-4-yl]-6-methyl-pyridine × 1 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;pH 5.6;291 K;23%(w/v) PEG 3350, 3%(v/v) glycerol at pH 5.6
分辨率 2.68 Å R-free 0.248
9FK5 Zebrafish Betaglycan Orphan Domain (zfBGo) in complex with TGF-B3 and extracellular domains of TGFBRI and TGFBRII 提交 2024-06-02 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 C 30–115(86 aa)
未记录 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.4
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 4.10 Å
9J9D Crystal structure of ALK5 kinase domain in complex with inhibitor HM-279 提交 2024-08-22 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa)
未记录 A1L30 2-((1-(but-2-yn-1-yl)-1H-pyrazol-4-yl)(cyclopropylmethyl)amino)-5-(4-(dimethylcarbamoyl)-1H-pyrrol-2-yl)thiazole-4-carboxamide × 1 EDO 1,2-ETHANEDIOL × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;20-25% PEG8000, 0.2 M Na acetate, 0.1 M Tris-HCl pH8.5
分辨率 1.34 Å R-free 0.209
9SUV Structure of an inhibitor of Human TGF-beta Type I Receptor 提交 2025-09-30 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 200–503(304 aa)
未记录 A1JQO ~{N}-[4-[[6-(5-chloranyl-2-fluoranyl-phenyl)-3-(2-hydroxyethylsulfanyl)pyridazin-4-yl]amino]pyridin-2-yl]-3-(4-methylpiperazin-1-yl)propanamide × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;295 K;0.2 M potassium thiocyanate 20 % w/v PEG 3350
分辨率 1.50 Å R-free 0.211